These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 32350238)

  • 1. Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment.
    Liu W; Lin H; He X; Chen L; Dai Y; Jia W; Xue X; Tao J; Chen L
    Transl Psychiatry; 2020 Apr; 10(1):125. PubMed ID: 32350238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis on CSF neurogranin levels for the diagnosis of Alzheimer's disease and mild cognitive impairment.
    Mavroudis IA; Petridis F; Chatzikonstantinou S; Kazis D
    Aging Clin Exp Res; 2020 Sep; 32(9):1639-1646. PubMed ID: 31463927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The synaptic marker neurogranin as a disease state biomarker in Alzheimer's disease: a systematic review and meta-analysis.
    Wang Z; Yang J; Zhu W; Tang Y; Jia J
    Int J Neurosci; 2022 Dec; 132(12):1245-1253. PubMed ID: 33527855
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
    Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
    J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Associations of Phosphorylated Tau 181 and Tau 231 Levels in Plasma and Cerebrospinal Fluid with Cognitive Function in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Li Z; Fan Z; Zhang Q
    J Alzheimers Dis; 2024; 98(1):13-32. PubMed ID: 38339929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic utility of CSF neurogranin in predicting future cognitive decline in the Alzheimer's disease continuum: A systematic review and meta-analysis with narrative synthesis.
    Yoong SQ; Lu J; Xing H; Gyanwali B; Tan YQ; Wu XV
    Ageing Res Rev; 2021 Dec; 72():101491. PubMed ID: 34688925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays.
    Öhrfelt A; Dumurgier J; Zetterberg H; Vrillon A; Ashton NJ; Kvartsberg H; Bouaziz-Amar E; Hugon J; Paquet C; Blennow K
    Alzheimers Res Ther; 2020 Dec; 12(1):168. PubMed ID: 33353563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF neurogranin levels as a biomarker in Alzheimer's disease and frontotemporal lobar degeneration: a cross-sectional analysis.
    Jurasova V; Andel R; Katonova A; Veverova K; Zuntychova T; Horakova H; Vyhnalek M; Kolarova T; Matoska V; Blennow K; Hort J
    Alzheimers Res Ther; 2024 Sep; 16(1):199. PubMed ID: 39242539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study.
    Vrillon A; Mouton-Liger F; Martinet M; Cognat E; Hourregue C; Dumurgier J; Bouaziz-Amar E; Brinkmalm A; Blennow K; Zetterberg H; Hugon J; Paquet C
    Alzheimers Res Ther; 2022 May; 14(1):71. PubMed ID: 35606871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer's Disease.
    Smailovic U; Kåreholt I; Koenig T; Ashton NJ; Winblad B; Höglund K; Nilsson P; Zetterberg H; Blennow K; Jelic V
    J Alzheimers Dis; 2021; 83(1):355-366. PubMed ID: 34334389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
    Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
    Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease.
    Mouton-Liger F; Dumurgier J; Cognat E; Hourregue C; Zetterberg H; Vanderstichele H; Vanmechelen E; Bouaziz-Amar E; Blennow K; Hugon J; Paquet C
    Alzheimers Res Ther; 2020 Jul; 12(1):88. PubMed ID: 32690068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.
    Kvartsberg H; Duits FH; Ingelsson M; Andreasen N; Öhrfelt A; Andersson K; Brinkmalm G; Lannfelt L; Minthon L; Hansson O; Andreasson U; Teunissen CE; Scheltens P; Van der Flier WM; Zetterberg H; Portelius E; Blennow K
    Alzheimers Dement; 2015 Oct; 11(10):1180-90. PubMed ID: 25533203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer's disease.
    Kivisäkk P; Carlyle BC; Sweeney T; Quinn JP; Ramirez CE; Trombetta BA; Mendes M; Brock M; Rubel C; Czerkowicz J; Graham D; Arnold SE
    Alzheimers Res Ther; 2022 Apr; 14(1):58. PubMed ID: 35461266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.
    Kester MI; Teunissen CE; Crimmins DL; Herries EM; Ladenson JH; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Nov; 72(11):1275-80. PubMed ID: 26366630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid growth-associated protein 43 levels in patients with progressive and stable mild cognitive impairment.
    Lu Y;
    Aging Clin Exp Res; 2022 Oct; 34(10):2399-2406. PubMed ID: 35988117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of cerebrospinal fluid neurogranin levels with cognition and neurodegeneration in Alzheimer's disease.
    Xue M; Sun FR; Ou YN; Shen XN; Li HQ; Huang YY; Dong Q; Tan L; Yu JT;
    Aging (Albany NY); 2020 May; 12(10):9365-9379. PubMed ID: 32421689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurodegeneration and Glial Activation Related CSF Biomarker as the Diagnosis of Alzheimer's Disease: A Systematic Review and an Updated Meta- analysis.
    Hao Y; Liu X; Zhu R
    Curr Alzheimer Res; 2022; 19(1):32-46. PubMed ID: 34879804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis.
    Liu D; Cao B; Zhao Y; Huang H; McIntyre RS; Rosenblat JD; Zhou H
    Neurosci Lett; 2018 Nov; 686():10-16. PubMed ID: 30171911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.